Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Eur Cell Mater ; 28: 152-63; discussion 163-5, 2014 Sep 22.
Article in English | MEDLINE | ID: mdl-25241965

ABSTRACT

Due to their well-established fracture risk reduction, bisphosphonates are the most frequently used therapeutic agent to treat osteoporosis. Bisphosphonates reduce fracture risk by suppressing bone resorption, but the lower bone turnover could have a negative impact on bone quality at the tissue level. Here, we directly assess the structural and mechanical characteristics of cancellous bone from the lumbar vertebrae (L5) in non-treated osteoporotic controls (n=21), mid-term alendronate-treated osteoporotic patients (n=6), and long-term alendronate-treated osteoporotic patients (n=7). The strength and toughness of single trabeculae were evaluated, while the structure was characterised through measurements of microdamage accumulation, mineralisation distribution, and histological indices. The alendronate-treated cases had a reduced eroded surface (ES/BS, p<0.001) and a higher bone mineralisation in comparison to non-treated controls (p=0.037), which is indicative of low turnover associated with treatment. However, the amount of microdamage and the mechanical properties were similar among the control and treatment groups. As the tissue mineral density (TMD) increased significantly with alendronate treatment compared to non-treated osteoporotic controls, the reduction in resorption cavities could counterbalance the higher TMD allowing the alendronate-treated bone to maintain its mechanical properties and resist microdamage accumulation. A multivariate analysis of the possible predictors supports the theory that multiple factors (e.g., body mass index, TMD, and ES/BS) can impact the mechanical properties. Our results suggest that long-term alendronate treatment shows no adverse impact on mechanical cancellous bone characteristics.


Subject(s)
Alendronate/pharmacology , Bone Density Conservation Agents/pharmacology , Calcification, Physiologic/drug effects , Lumbar Vertebrae/drug effects , Osteoporosis, Postmenopausal/drug therapy , Aged , Aged, 80 and over , Alendronate/adverse effects , Alendronate/therapeutic use , Biomechanical Phenomena , Bone Density Conservation Agents/adverse effects , Bone Density Conservation Agents/therapeutic use , Bone Resorption/drug therapy , Female , Humans , Lumbar Vertebrae/metabolism , Lumbar Vertebrae/pathology
2.
Biochem J ; 335 ( Pt 3): 631-6, 1998 Nov 01.
Article in English | MEDLINE | ID: mdl-9794804

ABSTRACT

Carba-NAD and pseudocarba-NAD are carbocyclic analogues of NAD+ in which a 2,3-dihydroxycyclopentane methanol replaces the beta-d-ribonucleotide ring of the nicotinamide riboside moiety of NAD+ [Slama and Simmons (1988) Biochemistry 27, 183-193]. These carbocyclic NAD+ analogues, related to each other as diastereomers, have been tested as inhibitors of the intrinsic NAD+ glycohydrolase activity of human CD38, dog spleen NAD+ glycohydrolase, mouse CD38 and Aplysia californica cADP-ribose synthetase. Pseudocarba-NAD, the carbocyclic dinucleotide in which l-2,3-dihydroxycyclopentane methanol replaces the d-ribose of the nicotinamide riboside moiety of NAD+, was found to be the more potent inhibitor. Pseudocarba-NAD was shown to inhibit the intrinsic NAD+ glycohydrolase activity of human CD38 competitively, with Ki=148 microM determined for the recombinant extracellular protein domain and Ki=180 microM determined for the native protein expressed as a cell-surface enzyme on cultured Jurkat cells. Pseudocarba-NAD was shown to be a non-competitive inhibitor of the purified dog spleen NAD+ glycohydrolase, with Kis=47 miroM and Kii=198 microM. Neither pseudocarba-NAD nor carba-NAD inhibited mouse CD38 or Aplysia californica cADP-ribose synthetase significantly at concentrations up to 1 mM. The results underscore significant species differences in the sensitivity of these enzymes to inhibition, and indicate that pseudocarba-NAD will be useful as an inhibitor of the enzymic activity of human but not mouse CD38 in studies using cultured cells.


Subject(s)
Antigens, CD/metabolism , Antigens, Differentiation/metabolism , NAD+ Nucleosidase/antagonists & inhibitors , NAD+ Nucleosidase/metabolism , NAD/analogs & derivatives , NAD/pharmacology , ADP-ribosyl Cyclase , ADP-ribosyl Cyclase 1 , Animals , Aplysia/enzymology , Cell Membrane/metabolism , Dogs , Humans , Isoniazid/pharmacology , Jurkat Cells , Kinetics , Membrane Glycoproteins , Mice , Recombinant Proteins/metabolism , Spleen/enzymology , Structure-Activity Relationship , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...